Lohith Gowda, MD
Hematology · New Haven, CTNPI 1669610168
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,977 of the $4,996 with a category attached, or 99.6%. Bristol Myers Squibb accounts for 69.3% of it on its own, with 2 other manufacturers making up the rest. 2021 is the largest year on record at $3,460, 2.3 times the $1,517 reported in 2019.
Across 3 payments — averaging $1665.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$3K
- Taiho Oncology, Inc.$2K
- Sobi, Inc$19
Across 42 payments — averaging $3021.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$75K
- Bristol Myers Squibb$52K
What the payments were for
- Speaking & faculty fees$4,977100%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 1 | $3,460 |
| Taiho Oncology, Inc. | 1 | $1,517 |
| Sobi, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vidaza$3,460
How this compares
$4,996 in reported general payments places this provider in the 65th percentile of 24 hematology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 30 | $461,507 |
| Valganciclovir Hcl | 11 | $3,249 |
| Acyclovir | 30 | $453 |
| Pantoprazole Sodium | 13 | $91 |
Paid to pharmacies, not to this prescriber.
Other hematology in New Haven
- Thomas DuffyNew Haven$298K
- Layla van DorenNew Haven$142K
- Nikolai PodoltsevNew Haven$123K
- Thomas PrebetNew Haven$42K
- Natalia NeparidzeNew Haven$13K
- Anish ShardaNew Haven$10K
- Alan LebowitzNew Haven$144
- Richard TorresNew Haven$120
- Yifei ZhangNew Haven$71
- Stephanie HaleneNew Haven$31
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.